share_log

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Price Target Cut to €57.95

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Price Target Cut to €57.95

Fresenius Medical Care AG&Co.KGaA(纽约证券交易所市场代码：FMS)目标价下调至57.95欧元
Defense World ·  2022/08/12 05:21

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) had its price target cut by research analysts at Berenberg Bank from €76.70 ($78.27) to €57.95 ($59.13) in a research report issued to clients and investors on Wednesday, The Fly reports.

Fresenius Medical Care AG&Co.KGaA(纽约证券交易所代码：FMS-GET评级)在周三发布给客户和投资者的一份研究报告中，贝伦贝格银行的研究分析师将其目标价从76.70欧元(78.27美元)下调至57.95欧元(59.13美元)。

Several other brokerages have also recently issued reports on FMS. Truist Financial reduced their target price on shares of Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a "hold" rating for the company in a report on Wednesday, June 22nd. StockNews.com cut shares of Fresenius Medical Care AG & Co. KGaA from a "strong-buy" rating to a "buy" rating in a report on Friday, July 15th. Jefferies Financial Group raised shares of Fresenius Medical Care AG & Co. KGaA from an "underperform" rating to a "buy" rating and raised their target price for the stock from $30.30 to $33.70 in a report on Monday, June 27th. UBS Group lowered shares of Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "neutral" rating in a research report on Friday, July 29th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.04) to €23.00 ($23.47) in a research report on Monday, August 1st. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $45.83.

其他几家券商最近也发布了关于FMS的报告。Truist Financial在6月22日周三的一份报告中将Fresenius Medical Care AG&Co.KGaA的目标价从34.00美元下调至27.00美元，并将该公司的评级设定为持有。在7月15日星期五的一份报告中，StockNews.com将Fresenius Medical Care AG&Co.KGaA的股票评级从“强势买入”下调至“买入”。在6月27日周一的一份报告中，杰富瑞金融集团将费森尤斯医疗保健股份公司的股票评级从表现不佳上调至买入，并将该股的目标价从30.30美元上调至33.70美元。在7月29日星期五的一份研究报告中，瑞银集团将费森尤斯医疗保健股份公司的股票评级从买入下调至中性。最后，摩根大通在8月1日周一的一份研究报告中将费森尤斯医疗保健公司KGaA的目标股价从51.00欧元(合52.04美元)下调至23.00欧元(合23.47美元)。一名分析师对该股的评级为卖出，七名分析师给出了持有评级，四名分析师对该公司给予了买入评级。根据MarketBeat.com的数据，该公司目前的平均评级为持有，平均目标价为45.83美元。

Get
到达
Fresenius Medical Care AG & Co. KGaA
费森尤斯医疗保健股份公司
alerts:
警报：

Fresenius Medical Care AG & Co. KGaA Trading Up 0.5 %

费森尤斯医疗保健股份公司KGaA股价上涨0.5%。

NYSE FMS opened at $18.85 on Wednesday. The company has a fifty day simple moving average of $23.68 and a two-hundred day simple moving average of $29.31. The stock has a market cap of $11.05 billion, a P/E ratio of 12.02, a P/E/G ratio of 0.92 and a beta of 1.02. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $18.16 and a 12-month high of $40.85. The company has a current ratio of 1.18, a quick ratio of 0.85 and a debt-to-equity ratio of 0.47.

纽约证交所FMS周三开盘报18.85美元。该公司的50日简单移动均线切入位23.68美元，200日简单移动均线切入位29.31美元。该股市值为110.5亿美元，市盈率为12.02，市盈率为0.92，贝塔系数为1.02。费森尤斯医疗保健股份公司(Fresenius Medical Care AG&Co.KGaA)的股价为18.16美元，为12个月低点，12个月高位为40.85美元。该公司的流动比率为1.18，速动比率为0.85，债务权益比率为0.47。

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

对冲基金买入费森尤斯医疗保健股份公司KGaA

A number of institutional investors and hedge funds have recently bought and sold shares of FMS. Pzena Investment Management LLC boosted its position in Fresenius Medical Care AG & Co. KGaA by 47.6% during the fourth quarter. Pzena Investment Management LLC now owns 9,459,446 shares of the company's stock worth $307,054,000 after acquiring an additional 3,051,672 shares during the last quarter. First Trust Advisors LP raised its stake in Fresenius Medical Care AG & Co. KGaA by 15.1% during the fourth quarter. First Trust Advisors LP now owns 1,925,326 shares of the company's stock worth $62,496,000 after purchasing an additional 252,768 shares during the period. Bank of America Corp DE raised its stake in Fresenius Medical Care AG & Co. KGaA by 27.9% during the first quarter. Bank of America Corp DE now owns 1,083,689 shares of the company's stock worth $36,499,000 after purchasing an additional 236,459 shares during the period. Cambiar Investors LLC raised its stake in Fresenius Medical Care AG & Co. KGaA by 18.3% during the first quarter. Cambiar Investors LLC now owns 1,363,874 shares of the company's stock worth $45,935,000 after purchasing an additional 210,819 shares during the period. Finally, Invesco Ltd. raised its stake in Fresenius Medical Care AG & Co. KGaA by 54.0% during the fourth quarter. Invesco Ltd. now owns 376,173 shares of the company's stock worth $12,211,000 after purchasing an additional 131,870 shares during the period. 4.73% of the stock is currently owned by institutional investors and hedge funds.
一些机构投资者和对冲基金最近买卖了FMS的股票。Pzena Investment Management LLC第四季度将其在费森尤斯医疗保健股份公司(Fresenius Medical Care AG&Co.KGaA)的头寸增加了47.6%。Pzena Investment Management LLC在上个季度额外收购了3,051,672股后，现在拥有9,459,446股该公司股票，价值307,054,000美元。First Trust Advisors LP第四季度将其在费森尤斯医疗保健股份公司(Fresenius Medical Care AG&Co.KGaA)的持股增加了15.1%。First Trust Advisors LP现在拥有1,925,326股该公司的股票，价值62,496,000美元，在此期间又购买了252,768股。美国银行第一季度将其在Fresenius Medical Care AG&Co.KGaA的持股比例提高了27.9%。美国银行DE目前持有1,083,689股该公司股票，价值36,499,000美元，在此期间又购买了236,459股。Cambiar Investors LLC在第一季度增持了费森尤斯医疗保健股份公司(Fresenius Medical Care AG&Co.KGaA)18.3%的股份。Cambiar Investors LLC现在拥有1,363,874股该公司的股票，价值45,935,000美元，在此期间又购买了210,819股。最后，景顺在第四季度将其在Fresenius Medical Care AG&Co.KGaA的持股比例提高了54.0%。景顺股份有限公司目前持有376,173股该公司股票，价值12,211,000美元，在此期间又购买了131,870股。4.73%的股票目前由机构投资者和对冲基金持有。

Fresenius Medical Care AG & Co. KGaA Company Profile

费森尤斯医疗保健股份公司简介

(Get Rating)

(获取评级)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Fresenius Medical Care AG&Co KGaA在德国、北美和国际上提供透析护理和相关的透析护理服务。它通过门诊透析诊所网络提供透析治疗以及相关的实验室和诊断服务；材料、培训和患者支持服务，包括临床监测、后续援助和安排将用品运送到患者住所；以及根据合同向美国医院提供为住院的终末期肾病(ESRD)患者和急性肾功能衰竭患者提供的透析服务。

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on Fresenius Medical Care AG & Co. KGaA (FMS)
  • Look at Honeywell for a Steady and Diversified Stock
  • Why Invest in High-Yield Dividend Stocks?
  • Find and Profitably Trade Stocks at 52-Week Lows
  • Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
  • Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
  • 免费获取StockNews.com关于Fresenius Medical Care AG&Co.KGaA(FMS)的研究报告。
  • 霍尼韦尔看好稳定和多元化的股票
  • 为什么要投资高收益股利股票？
  • 找到并获利于52周低点的股票交易
  • 迪士尼(NYSE：DIS)的股票刚刚给了投资者一个巨大的信号
  • 清洁能源法案通过后，太阳能股大放异彩

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

接受Fresenius Medical Care AG&Co.KGaA Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Fresenius Medical Care AG&Co.KGaA和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发